Market capitalization | $34.46m |
Enterprise Value | $-36.84m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 1.91 |
EV/Sales (TTM) EV/Sales | -3.08 |
P/S ratio (TTM) P/S ratio | 2.88 |
P/B ratio (TTM) P/B ratio | 1.24 |
Revenue growth (TTM) Revenue growth | 77.01% |
Revenue (TTM) Revenue | $11.98m |
As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.
4 Analysts have issued a LAVA Therapeutics NV forecast:
4 Analysts have issued a LAVA Therapeutics NV forecast:
Dec '24 |
+/-
%
|
||
Revenue | 12 12 |
77%
77%
|
|
Gross Profit | - - |
-
|
|
EBITDA | -29 -29 |
-
|
EBIT (Operating Income) EBIT | -30 -30 |
32%
32%
|
Net Profit | -25 -25 |
40%
40%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The firm develops next generation T-cell engaging bispecific antibodies to treat cancer. The company was founded by Erik van den Berg in 2016 and is headquartered in Utrecht, the Netherlands.
Head office | Netherlands |
CEO | Stephen Hurly |
Employees | 34 |
Founded | 2016 |
Website | www.lavatherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.